Oncotelic Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Oncotelic Therapeutics has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 45.6% per year.
Información clave
9.9%
Tasa de crecimiento de los beneficios
46.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | -45.6% |
Rentabilidad financiera | -13.1% |
Margen neto | -1,770.3% |
Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Oncotelic Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 0 | -1 | 0 | 0 |
31 Mar 24 | 0 | -8 | 1 | 0 |
31 Dec 23 | 0 | -8 | 1 | 0 |
30 Sep 23 | 0 | -12 | 1 | 0 |
30 Jun 23 | 0 | -13 | 1 | 0 |
31 Mar 23 | 0 | 9 | 1 | 0 |
31 Dec 22 | 0 | 5 | 5 | 1 |
30 Sep 22 | 0 | 9 | 5 | 1 |
30 Jun 22 | 0 | 8 | 6 | 2 |
31 Mar 22 | 0 | -11 | 9 | 3 |
31 Dec 21 | 0 | -9 | 5 | 4 |
30 Sep 21 | 0 | -11 | 5 | 6 |
30 Jun 21 | 0 | -11 | 5 | 6 |
31 Mar 21 | 1 | -8 | 3 | 6 |
31 Dec 20 | 2 | -10 | 5 | 4 |
30 Sep 20 | 2 | -10 | 5 | 2 |
30 Jun 20 | 2 | -9 | 5 | 1 |
31 Mar 20 | 0 | -10 | 5 | 1 |
31 Dec 19 | 0 | -7 | 3 | 1 |
30 Sep 19 | 0 | -3 | 2 | 1 |
30 Jun 19 | 0 | -3 | 1 | 1 |
31 Mar 19 | 0 | -2 | 1 | 1 |
31 Dec 18 | 0 | -1 | 0 | 1 |
Ingresos de calidad: OTLC is currently unprofitable.
Margen de beneficios creciente: OTLC is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: OTLC is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.
Acelerando crecimiento: Unable to compare OTLC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: OTLC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: OTLC has a negative Return on Equity (-13.07%), as it is currently unprofitable.